Abstract
Cytokines are key mediators of cellular communication and regulators of biological advents. The timing, quantity and localization of cytokines are key features in producing specific biological outcomes, and thus have been thoroughly studied and reviewed while continuing to be a focus of the cytokine biology community. Due to the complexity of cellular signaling and multitude of factors that can affect signaling outcomes, systemic level studies of cytokines are ongoing. Despite their small size, cytokines can exhibit structurally promiscuous and dynamic behavior that plays an equally important role in biological activity. In this review using case studies, we highlight the recent insight gained from observing cytokines through a molecular lens and how this may complement a system-level understanding of cytokine biology, explain diversity of downstream signaling events, and inform therapeutic and experimental development.
Introduction
Cytokines are small signaling proteins that serve as effectors of immunity and require spatial or temporal expression to regulate biological outcomes (). Cytokines are especially prevalent in disease states where their presence can indicate pathological progression or conversely, a protective effect. For example, signaling cascades that maintain homeostatic balance use cytokines to coordinate appropriate responses that initiate or terminate inflammation. The lens through which researchers often view cytokine biochemistry involves their localization and quantity, using phenomenological models to derive system-level explanations of function (). Despite the utility of this approach, the molecular aspects of cytokine function remain unclear, hindering efforts to intuitively modulate their mechanisms and promiscuous interactions. Understanding the structural and environmental factors that stimulate transformations of cytokines is critical to disentangling their role in biological events. Such insight can inform 1) the role played by cytokines as agents of cellular communication, 2) the improvement of tools leveraged for research, and 3) the development of cytokines as therapeutics or targets in clinical treatment plans. In the past decade, many enzymes and metabolic proteins that accommodate multiple non-overlapping functions by “moonlighting” have been shown to utilize intrinsic protein dynamics as a mechanistic driving force (Mani et al., 2015; ; ; ). However, structural plasticity in cytokines with broadly demonstrated abilities to harbor multiple functions within compact scaffolds has not been as thoroughly investigated as a moonlighting mechanism.
Researchers use cytokines to replicate immunological conditions in the laboratory in order to study behaviors of specific cell types (Schluns and Lefrançois, 2003; ; Roan et al., 2019), to replicate extracellular environments, to observe biological responses in vitro (; ; ), and as a measurable biomarker of disease. Cytokines are also used as therapeutics in clinical settings to specifically stimulate immune responses, including interleukins (ILs) in cancer and colony-stimulating factors (CSFs) in general neutropenia (Mehta et al., 2015; ; ). Given the breadth of the roles played by cytokines intrinsically and as research tools or in clinical settings (i.e. from bench to bedside), it is clear that having thorough understanding of the mechanisms driving cytokine function is crucial. One factor that complicates structure-function investigations of cytokines, and the establishment of general rules that govern their function, is the fact that these proteins exert a great deal of their influence under conditions of disease, which are more difficult to mimic in structural characterizations. In this Review, we discuss current efforts to define the mechanisms of cytokines at the “residue level,” where changes in atomic structure or conformational dynamics of the protein yields information relevant to physiological scenarios. We highlight case studies of cytokines with emerging diverse roles, while also showcasing experimental and theoretical approaches for understanding cytokine biochemistry. Though we cannot comprehensively discuss every avenue of investigation in this Review (; ; ; ; Park et al., 2017; ; Penk et al., 2019; ; Roy, 2020; Yang, 2020), each of the case studies below offers a useful piece insight into an extremely complex class of biomolecules that may aid in the development of broadly applicable strategies to study molecular interactions.
Case Study I: Macrophage Migration Inhibitory Factor
Macrophage migration inhibitory factor (MIF) is implicated in a wide range of disease states, where elevated MIF levels are markers for tumorigenesis (; Noe and Mitchell, 2020), sepsis (Toldi et al., 2021), acute respiratory distress syndrome (ARDS) (; ), arthritis (Onodera et al., 1999; ; ), colitis (), and Malaria (; Sun et al., 2012; ). MIF is highly conserved in diverse organisms and is heavily involved in inflammatory responses, cell cycle control, the sensing of pathogenic stimuli, activation of innate defense responses, recruitment of immune cells, and prevention of p53-mediated apoptosis (; Mitchell et al., 2002). Despite a compact structural scaffold and a lack of clear modular domains, MIF contains several sequence motifs, including two enzymatic sites for disparate tautomerase and oxidoreductase activities (a third nuclease activity was recently proposed), that provide MIF with a surprising functional complexity (; Lubetsky et al., 1999; Wang et al., 2021). MIF is also remarkably amenable to interactions with a number of target proteins, despite its overall architectural rigidity (Mühlhahn et al., 1996), and is proposed to be involved, directly or indirectly, in 49 signaling events. (Subbannayya et al., 2016). This functional promiscuity necessitates an intimate understanding of the mechanism(s) that govern its cellular interactions, but also complicate efforts to assign any singular function to MIF with a high level of mechanistic detail.
Efforts to understand MIF at the molecular level have focused on 1) studies of mutations that affect its structure and function, 2) studies of signaling within its homotrimeric structure, and 3) studies of interactions between MIF and drug-like molecules (Lubetsky et al., 1999; Mühlhahn et al., 1996; Pantouris et al., 2015; Pantouris et al., 2020; ; Trivedi-Parmar and Jorgensen, 2018; ; ; Takahashi et al., 2009). Site-directed mutagenesis has been employed by several laboratories to examine the structural and biological impact of perturbations to the MIF catalytic and receptor binding sites (Pantouris et al., 2015; Pantouris et al., 2020; ; ; Oda et al., 2008; ; ). X-ray crystallographic reports of >100 MIF structures in the Protein Data Bank show essentially no observable changes in response to mutations, substrates or inhibitors, suggesting MIF is highly rigid and resistant to architectural deformation. However, identical solution NMR experiments show that atomic level fingerprints of MIF variants are unique, indicating that the local structure of MIF is in fact quite flexible in solution and may play a significant role in modulating its biochemistry (Pantouris et al., 2018; Schinagl et al., 2018). More recent work has leveraged these findings to explore the existence of signaling pathways that propagate chemical information between distant regions of the MIF structure. Pantouris, et al characterized two such pathways in successive reports, first demonstrating through molecular dynamics (MD) simulations that nanosecond timescale conformational fluctuations were critical to the organization of the binding interface for the MIF-induced activation of CD74 (Pantouris et al., 2015). Further analysis of correlated dynamics in MIF revealed the CD74 activation signal to originate from a previously uncharacterized residue, Tyr99, at the solvent channel formed by the three-fold symmetric MIF structure (Figure 1A). Interestingly, this allosteric site modulates the dynamics of the MIF protein on multiple timescales when mutated, and not only affects CD74 activation in vivo, but also regulates tautomerase enzymatic activity (Figure 1B) through a different signaling pathway originating from Tyr99 (Pantouris et al., 2018; Pantouris et al., 2020; Parkins et al., 2021). The factors that influence the ramping up or down of MIF enzymatic activity include protein dynamics, intramolecular hydrogen bonds and hydrogen bonds with solvent molecules, and pi-stacking interactions from aromatic side chains lining the signaling pathway. At present, it is still unclear how, or if, CD74 activation or tautomerase activity are preferentially activated in the cell. Nonetheless, recent solution studies of MIF revealed two of its biochemical functions to be connected by a region of its structure previously uncharacterized at the molecular level. Numerous studies of MIF in complex with drugs and other modulators have never targeted the Tyr99 regulatory site, but have modulated the same enzymatic and CD74 activities from different locations within MIF, (; ; Trivedi-Parmar and Jorgensen, 2018), presenting a new avenue for structure-function evaluations.
FIGURE 1
Case Study II: Granulocyte Macrophage Colony-Stimulating Factor
Granulocyte macrophage colony-stimulating factor (GMCSF) is involved in myelopoiesis (; Ushach and Zlotnik, 2016), immunomodulation (Lotfi et al., 2019), and pro-inflammatory signaling (; ), specifically the promotion of alveolar macrophage activity leading to surfactant accumulation in the lungs (; ). GMCSF has been shown to aggravate conditions such as rheumatoid arthritis and multiple sclerosis (van Nieuwenhuijze et al., 2013; Shiomi et al., 2016), but it can also ameliorate diseases such as type-I diabetes (), and is used clinically to combat neutropenia (Mehta et al., 2015). As such, it is a clear example of a cytokine that performs both beneficial and pathological functions. Interestingly, several studies have identified alternate receptor conformations of stoichiometric assembly that can lead to receptor activation (i.e. cell survival, activation, or differentiation) (; ) and beyond its receptor structure, GMCSF itself has been shown to adopt different structural and dynamic properties dependent on the pH of its chemical environment, which may contribute to its modular signaling or suggest additional non-overlapping roles for GMCSF ().
The GMCSF structure has been studied by X-ray crystallography (Rozwarski et al., 1996), and more recently NMR spectroscopy (), providing unique insight into its overall fold and plasticity. One particular aspect of GMCSF function that has benefitted substantially from atomic level studies has been the knowledge of its interactions with clinically relevant molecules. In these cases, there has been particular interest in understanding how GMCSF, a clinically administered protein with a promiscuous interactome, could interfere with other therapeutics under conditions of disease. For example, Wettreich and coworkers showed GMCSF to form pH-dependent complexes with heparin, another widely used therapeutic, via analytical chromatography and light scattering (Wettreich et al., 1999). These experiments proposed a binding mechanism and laid the groundwork for understanding how signaling proteins like GMCSF can be tuned by environmental stimuli to form selective ligand complexes. The GMCSF-heparin interaction has since been resolved at the atomic level with NMR spectroscopy under varied solution pH conditions and in the presence of precisely controlled heparin oligosaccharide chain lengths (). The GMCSF protein was found to undergo pH-dependent structural and dynamic changes that modulated its affinity for heparin. Such a pH shift would occur at air-lung interfaces or in tumor microenvironments and was proposed to be essential for the ionization of three histidine residues that nucleate the heparin and the stimulation of multi-timescale dynamics that shift the conformation of N-terminal α-helices to expose the binding pocket. NMR chemical shifts mapped the heparin binding site and relaxation experiments, supported by molecular simulations, confirmed a high level of conformational flexibility along the binding interface and proposed a model for the complex structure (Figure 1C). This binding interaction is dependent not only on the accessibility of the binding pocket, but the size of the heparin as well, where heparins able to span the anchor points at the histidine triad (Figure 1D) and the adjacent flexible linker with several lysine residues bind with greater affinity than smaller chain heparins.
Atomic level studies of GMCSF mapped a clinically-relevant interaction to reveal the binding site and the biophysical factors that influence its accessibility to ligands. This work also reinforced an important aspect of cytokine biochemistry that is intimately tied to the hypothesized dynamic mechanisms of action; the utility of conducting biophysical studies in regimes beyond those of “ideal” conditions. In this case, if GMCSF were only characterized based on its presence in a certain niche (i.e. a microenvironment at neutral pH mimicking only circulating GMCSF), the resulting biochemical outcomes would not have captured its high affinity state for heparin and a gap in our understanding of its mechanism(s) would remain. Put another way, if GMCSF is expressed in high quantities in acidic environments and in the presence of high heparin concentrations, a measurable amount of biological activity presumed to be related to the GMCSF concentration would likely not correlate with its expected activity-to-quantity ratio.
Case Study III: Interleukin-1
Interleukins are a diverse class of cytokines with low sequence identity that are secreted by several cell types (beyond the originally presumed leukocyte-specific secretion that spawned their name). One subclass, the interleukin (IL)-1 family, comprises 11 pro- and anti-inflammatory cytokines that have abnormal expression profiles in many autoimmune diseases (), which presumably affects their signal transduction by the IL-1 receptor (IL-1R). Interestingly, Ge et al recently demonstrated that IL-1R regulates its signaling activity via structural dynamics (). Most IL-1 family members are commonly expressed as full-length precursors that require proteolytic processing for biologically mature forms, leading to significant structural variability. IL-1α is cleaved by the cysteine protease calpain, whereas IL-1β and IL-18 require proteolytic cleavage by the inflammasome (; van de Veerdonk et al., 2011). IL-33 and IL-36 utilize neutrophil proteinases such as elastase and proteinase-3 (), while IL-37 is cleaved by capsase-1 () and IL-38 is bioactive as a full-length molecule. Mechanisms between members of the IL-1 family differ in binding interactions with the receptor machinery as Günther et al. have shown that IL-1β and IL-33 use different molecular mechanisms for engaging with the IL-1 receptor accessory protein (IL-1Ra) (). While Hou et al. took an alternate approach by leveraging different binding characteristics of IL-1β and IL-1Ra to engineer chimeric receptor antagonists of IL-1R to alleviate the chronically inflammatory dry eye disease ().
Several groups have explored the biophysical aspects of these structures in order to understand how IL-1s transduce signals throughout the cell. One example is the computational approach taken by Ozbabakan et al to map the structural postures of IL-1, IL-1R1 and IL-1RAP as well as downstream signaling proteins (such as MYD88 and TOLLIP) when previously identified oncogenic SNPs cause changes in amino acid residues (). This study highlights the change in protein dynamics and its subsequent effect on an entire downstream signaling pathway. The authors present a computationally derived structural pathway detailing the conformational changes related to IL-1 signaling, revealing the mechanisms behind mutations that lead to oncogenic consequences. This work is one example that underscores the importance of atomistic shifts in cytokine structure (rather than a global ensemble) as valuable in the pursuit of targeted therapies and explorations of regulatory mechanisms.
Case Study IV: Interleukin-2
IL-2 is produced predominantly by activated T-cells in secondary lymphoid organs, where it is consumed by these and other CD25+ cells, including regulatory T-cells (TReg) and lymphocytes. IL-2 has been used in both agonistic and antagonistic contexts for immunotherapies, including 1) low-dose efforts to increase TReg cell counts in autoimmunity, chronic inflammatory conditions and graft rejection (Tahvildari and Dana, 2019) and 2) high-dose administration to expand cytotoxic lymphocyte populations for the treatment of metastatic cancer (; ). Efforts to understand the signaling mechanism and therapeutic potential of IL-2 have focused primarily on cellular and live animal studies, though others have tackled questions relating to its molecular structure and conformational landscape.
Critically, it has been established that IL-2 adopts discrete structures in solution that are populated via allosteric activation as shown by Sgourakis and coworkers (). These results build upon a previous body of literature that clearly demonstrate divergent cell fates based on signaling related to the structural plasticity of IL-2. Specifically, methyl-based chemical exchange NMR spectroscopy interrogated IL-2 dynamics on a timescale (μs-ms) relevant to enzyme catalysis, ligand binding, and allostery (Figures 2A,B) (). The authors reported that a flexible loop between two N-terminal α-helices acts as a switch (Figure 2C), toggling between an autoinhibited state that has greater affinity for antibody binding, leading to proliferation of Treg cell populations, and a productive state, where IL-2 is primed to interact with IL-2 receptor-α, leading to activation of Teff (effector) cell populations (). De Paula et al. go on to propose an allosteric network of residues serving as the link between the hydrophobic core of IL-2 and the AB loop (Figure 2B), highlighting how a focus on localized molecular motions can lead to novel and detailed mechanistic insight about a cytokine that can be both leveraged and accounted for in future therapeutic efforts.
FIGURE 2
Case Study V: Interleukin-17
IL-17 promotes inflammation and plays a protective role in antimicrobial immunity (McGeachy et al., 2019). In the latter case, IL-17 was shown to mediate protection against extracellular pathogens (Valeri and Raffatellu, 2016; ) by working with IL-22 (a related cytokine also produced by IL-17–expressing cells) to stimulate production of antimicrobial peptides (Wozniak et al., 2014; Mulcahy et al., 2016; Moyat et al., 2017). IL-17 is therefore a double-edged sword with biological properties that make it difficult to predict its role in inflammatory diseases with a polymicrobial etiology. It is possible that IL-17 exerts both protective and destructive effects, as suggested in distinct mouse models (; Milovanovic et al., 2020; ; ; Righetti et al., 2018; O'Connor Jr et al., 2009), although chronic IL-17 receptor signaling can turn a potentially protective acute inflammatory response into chronic immunopathology (Zenobia and Hajishengallis, 2015).
Despite its status as one of best studied cytokines in immunology, recent structure-function relationships and dynamic studies have provided new insight into its regulatory mechanism. Specifically, IL-17 conformational dynamics were shown to dictate signaling efficiency via a strong influence over binding affinity for this system. The structural interconversions of IL-17A and IL-17F were studied with NMR spectroscopy by Waters et al, where the IL-17A homodimer was demonstrated to be far more dynamic on slow timescales than the IL-17F homodimer or IL-17A/IL-17F heterodimer (Figure 2D). The aforementioned dynamics aid the IL-17A homodimer in toggling between at least two distinct conformations and the structural perturbations during this process were mapped to the receptor binding region (Waters et al., 2021). The authors propose that these structural fluctuations are likely to affect binding affinity to receptor A (but not other IL-17 receptors), providing insight into the activation of receptor signaling based on atomic level dynamics that cannot be resolved from systems level observations examining only the presence and quantity of IL-17.
Concluding Remarks
The mechanisms by which cytokines influence a large number of biochemical pathways and molecular interactions have been mysterious. The fact that most proteins in this class have very small structures with simple folds only adds to this paradox. It is difficult to link all of cytokine biochemistry with a common thread, primarily because the majority of information regarding cytokine functions comes from cellular or live animal studies, with comparatively few biophysical investigations. However, the current literature describing cytokine structure has generally shown that 1) protein dynamics that toggle active conformations of cytokines are a driver of functional promiscuity, 2) the cellular or chemical environment modulates cytokine structure and interactions with specific binding partners, and 3) despite their small size, mechanisms of cytokine regulation can be driven by principles of allostery and concerted motion.
Statements
Author contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Funding
This work was supported by Rhode Island Foundation Grant GR5290658.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
Acuner OzbabacanS. E.GursoyA.NussinovR.KeskinO. (2014). The Structural Pathway of Interleukin 1 (IL-1) Initiated Signaling Reveals Mechanisms of Oncogenic Mutations and SNPs in Inflammation and Cancer. Plos Comput. Biol.10. e100347010.1371/journal.pcbi.1003470
2
Altan-BonnetG.MukherjeeR. (2019). Cytokine-mediated Communication: a Quantitative Appraisal of Immune Complexity. Nat. Rev. Immunol.19, 205–217. 10.1038/s41577-019-0131-x
3
AntoniuS. A. (2010). GM-CSF Pathway Correction in Pulmonary Alveolar Proteinosis. Expert Opin. Biol. Ther.10, 1357–1365. 10.1517/14712598.2010.510507
4
Arango DuqueG.DescoteauxA. (2014). Macrophage Cytokines: Involvement in Immunity and Infectious Diseases. Front. Immunol.5, 491. 10.3389/fimmu.2014.00491
5
AubinY.GingrasG.SauvéS. (2008). Assessment of the Three-Dimensional Structure of Recombinant Protein Therapeutics by NMR Fingerprinting: Demonstration on Recombinant Human Granulocyte Macrophage-colony Stimulation Factor. Anal. Chem.80, 2623–2627. 10.1021/ac7026222
6
Azimzadeh IraniM.EjtehadiM. R. (2019). GAG Positioning on IL-1RI; A Mechanism Regulated by Dual Effect of Glycosylation. Glycobiology29, 803–812. 10.1093/glycob/cwz055
7
BachJ.-P.RinnB.MeyerB.DodelR.BacherM. (2008). Role of MIF in Inflammation and Tumorigenesis. Oncology75, 127–133. 10.1159/000155223
8
Baeza GarciaA.SiuE.SunT.ExlerV.BritoL.HekeleA.et al (2018). Neutralization of the Plasmodium-Encoded MIF Ortholog Confers Protective Immunity against Malaria Infection. Nat. Commun.9, 2714. 10.1038/s41467-018-05041-7
9
BarnesB. J.SomervilleC. C. (2020). Modulating Cytokine Production via Select Packaging and Secretion from Extracellular Vesicles. Front. Immunol.11, 1040. 10.3389/fimmu.2020.01040
10
BecherB.TuguesS.GreterM. (2016). GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation. Immunity45, 963–973. 10.1016/j.immuni.2016.10.026
11
BendratK.Al-AbedY.CallawayD. J. E.PengT.CalandraT.MetzC. N.et al (1997). Biochemical and Mutational Investigations of the Enzymatic Activity of Macrophage Migration Inhibitory Factor. Biochemistry36, 15356–15362. 10.1021/bi971153a
12
BerghausL. J.GiguèreS.BordinA. I.CohenN. D. (2018). Effects of Priming with Cytokines on Intracellular Survival and Replication of Rhodococcus Equi in Equine Macrophages. Cytokine102, 7–11. 10.1016/j.cyto.2017.12.011
13
BerraondoP.SanmamedM. F.OchoaM. C.EtxeberriaI.AznarM. A.Pérez-GraciaJ. L.et al (2019). Cytokines in Clinical Cancer Immunotherapy. Br. J. Cancer120, 6–15. 10.1038/s41416-018-0328-y
14
BhattacharyaP.BudnickI.SinghM.ThiruppathiM.AlharshawiK.ElshabrawyH.et al (2015). Dual Role of GM-CSF as a Pro-inflammatory and a Regulatory Cytokine: Implications for Immune Therapy. J. Interferon Cytokine Res.35, 585–599. 10.1089/jir.2014.0149
15
BlackR. A.KronheimS. R. K.CantrellM.DeeleyM. C.MarchC. J.PrickettK. S.et al (1988). Generation of Biologically Active Interleukin-1 Beta by Proteolytic Cleavage of the Inactive Precursor. J. Biol. Chem.263, 5. 10.1016/s0021-9258(19)76559-4
16
BorknerL.CurhamL. M.WilkM. M.MoranB.MillsK. H. G. (2021). IL-17 Mediates Protective Immunity against Nasal Infection with Bordetella Pertussis by Mobilizing Neutrophils, Especially Siglec-F+ Neutrophils. Mucosal Immunol.14, 1183–1202. 10.1038/s41385-021-00407-5
17
BoukourisA. E.ZervopoulosS. D.MichelakisE. D. (2016). Metabolic Enzymes Moonlighting in the Nucleus: Metabolic Regulation of Gene Transcription. Trends in Biochemical Sciences41, 712–730. 10.1016/j.tibs.2016.05.013
18
BroughtonS. E.HercusT. R.NeroT. L.DottoreM.McClureB. J.DhagatU.TaingH.GormanM. A.King-ScottJ.LopezA. F.ParkerM. W. (2016). Conformational Changes in the GM-CSF Receptor Suggest a Molecular Mechanism for Affinity Conversion and Receptor Signaling. Structure24, 1271–1281. 10.1016/j.str.2016.05.017
19
BuchbinderE. I.DutcherJ. P.DanielsG. A.CurtiB. D.PatelS. P.HoltanS. G.MiletelloG. P.FishmanM. N.GonzalezR.ClarkJ. I.RichartJ. M.LaoC. D.TykodiS. S.SilkA. W.McDermottD. F. (2019). Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. j. immunotherapy cancer7, 49. 10.1186/s40425-019-0522-3
20
ChenC.LiuH.ZabadS.RiveraN.RowinE.HassanM.Gomez De JesusS. M.Llinás SantosP. S.KravchenkoK.MikhovaM.KettererS.ShenA.ShenS.NavasE.HoranB.RaudseppJ.JefferyC. (2021). MoonProt 3.0: an update of the moonlighting proteins database. Nucleic Acids Res49, D368–D372. 10.1093/nar/gkaa1101
21
ChenC.ZabadS.LiuH.WangW.JefferyC. (2018). MoonProt 2.0: an Expansion and Update of the Moonlighting Proteins Database. Nucleic Acids Res.46, D640–D644. 10.1093/nar/gkx1043
22
ChoY.CrichlowG. V.VermeireJ. J.LengL.DuX.HodsdonM. E.et al (2010). Allosteric Inhibition of Macrophage Migration Inhibitory Factor Revealed by Ibudilast. Proc. Natl. Acad. Sci.107, 11313–11318. 10.1073/pnas.1002716107
23
ClancyD. M.SullivanG. P.MoranH. B. T.HenryC. M.ReevesE. P.McElvaneyN. G.et al (2018). Extracellular Neutrophil Proteases Are Efficient Regulators of IL-1, IL-33, and IL-36 Cytokine Activity but Poor Effectors of Microbial Killing. Cel Rep.22, 2937–2950. 10.1016/j.celrep.2018.02.062
24
ConlonK. C.MiljkovicM. D.WaldmannT. A. (2019). Cytokines in the Treatment of Cancer. J. Interferon Cytokine Res.39, 6–21. 10.1089/jir.2018.0019
25
CourniaZ.LengL.GandavadiS.DuX.BucalaR.JorgensenW. L. (2009). Discovery of Human Macrophage Migration Inhibitory Factor (MIF)-CD74 Antagonists via Virtual Screening. J. Med. Chem.52, 416–424. 10.1021/jm801100v
26
CruzA.FragaA. G.FountainJ. J.Rangel-MorenoJ.TorradoE.SaraivaM.et al (2010). Pathological Role of Interleukin 17 in Mice Subjected to Repeated BCG Vaccination after Infection with Mycobacterium tuberculosis. J. Exp. Med.207, 1609–1616. 10.1084/jem.20100265
27
CuiJ. Y.ZhangF.NierzwickiL.PalermoG.LinhardtR. J.LisiG. P. (2020). Mapping the Structural and Dynamic Determinants of pH-Sensitive Heparin Binding to Granulocyte Macrophage Colony Stimulating Factor. Biochemistry59, 3541–3553. 10.1021/acs.biochem.0c00538
28
DallenbachK.MaurerP.RöhnT.ZabelF.KopfM.BachmannM. F. (2015). Protective Effect of a Germline, IL-17-neutralizing Antibody in Murine Models of Autoimmune Inflammatory Disease. Eur. J. Immunol.45, 1238–1247. 10.1002/eji.201445017
29
de JongY. P.Abadia-MolinaA. C.SatoskarA. R.ClarkeK.RietdijkS. T.FaubionW. A.et al (2001). Development of Chronic Colitis Is Dependent on the Cytokine MIF. Nat. Immunol.2, 1061–1066. 10.1038/ni720
30
De PaulaV. S.JudeK. M.NerliS.GlassmanC. R.GarciaK. C.SgourakisN. G. (2020). Interleukin-2 Druggability Is Modulated by Global Conformational Transitions Controlled by a Helical Capping Switch. Proc. Natl. Acad. Sci. USA117, 7183–7192. 10.1073/pnas.2000419117
31
DinarelloC. A. (2018). Overview of the IL-1 Family in Innate Inflammation and Acquired Immunity. Immunol. Rev.281, 8–27. 10.1111/imr.12621
32
DonnellyS. C.HaslettC.ReidP. T.GrantI. S.WallaceW. A. H.MetzC. N.et al (1997). Regulatory Role for Macrophage Migration Inhibitory Factor in Acute Respiratory Distress Syndrome. Nat. Med.3, 320–323. 10.1038/nm0397-320
33
El-TurkF.CascellaM.Ouertatani-SakouhiH.NarayananR. L.LengL.BucalaR.et al (2008). The Conformational Flexibility of the Carboxy Terminal Residues 105−114 Is a Key Modulator of the Catalytic Activity and Stability of Macrophage Migration Inhibitory Factor†. Biochemistry47, 10740–10756. 10.1021/bi800603x
34
El-TurkF.FauvetB.AshrafiA.Ouertatani-SakouhiH.ChoM.-K.NeriM.et al (2012). Characterization of Molecular Determinants of the Conformational Stability of Macrophage Migration Inhibitory Factor: Leucine 46 Hydrophobic Pocket. PLoS One7. e4502410.1371/journal.pone.0045024
35
EyerichK.DimartinoV.CavaniA. (2017). IL-17 and IL-22 in Immunity: Driving protection and Pathology. Eur. J. Immunol.47, 607–614. 10.1002/eji.201646723
36
FanC.RajasekaranD.SyedM. A.LengL.LoriaJ. P.BhandariV.et al (2013). MIF Intersubunit Disulfide Mutant Antagonist Supports Activation of CD74 by Endogenous MIF Trimer at Physiologic Concentrations. Proc. Natl. Acad. Sci.110, 10994–10999. 10.1073/pnas.1221817110
37
FrydrychL. M.BianG.FattahiF.MorrisS. B.O’RourkeR. W.LumengC. N.et al (2019). GM-CSF Administration Improves Defects in Innate Immunity and Sepsis Survival in Obese Diabetic Mice. J.I.202, 931–942. 10.4049/jimmunol.1800713
38
GangeleK.GulatiK.JoshiN.KumarD.PoluriK. M. (2020). Molecular Insights into the Differential Structure-Dynamics-Stability Features of Interleukin-8 Orthologs: Implications to Functional Specificity. Int. J. Biol. Macromolecules164, 3221–3234. 10.1016/j.ijbiomac.2020.08.176
39
GeJ.RemeshS. G.HammelM.PanS.MahanA. D.WangS.et al (2019). Functional Relevance of Interleukin-1 Receptor Inter-domain Flexibility for Cytokine Binding and Signaling. Structure27, 1296–1307. e129510.1016/j.str.2019.05.011
40
GüntherS.DeredgeD.BowersA. L.LuchiniA.BonsorD. A.BeadenkopfR.et al (2017). IL-1 Family Cytokines Use Distinct Molecular Mechanisms to Signal through Their Shared Co-receptor. Immunity47, 510–523. e51410.1016/j.immuni.2017.08.004
41
HamiltonJ. A. (2019). GM-CSF-Dependent Inflammatory Pathways. Front. Immunol.10, 2055. 10.3389/fimmu.2019.02055
42
HanC.LinY.ShanG.ZhangZ.SunX.WangZ.et al (2010). Plasma Concentration of Malaria Parasite-Derived Macrophage Migration Inhibitory Factor in Uncomplicated Malaria Patients Correlates with Parasitemia and Disease Severity. Clin. Vaccin. Immunol17, 1524–1532. 10.1128/CVI.00149-10
43
HansenG.HercusT. R.McClureB. J.StomskiF. C.DottoreM.PowellJ.et al (2008). The Structure of the GM-CSF Receptor Complex Reveals a Distinct Mode of Cytokine Receptor Activation. Cell134, 496–507. 10.1016/j.cell.2008.05.053
44
HerringC. A.SingerC. M.ErmakovaE. A.KhairutdinovB. I.ZuevY. F.JacobsD. J.et al (2015). Dynamics and Thermodynamic Properties of CXCL7 Chemokine. Proteins83, 1987–2007. 10.1002/prot.24913
45
HouJ.TownsonS. A.KovalchinJ. T.MasciA.KinerO.ShuY.et al (2013). Design of a superior Cytokine Antagonist for Topical Ophthalmic Use. Proc. Natl. Acad. Sci.110, 3913–3918. 10.1073/pnas.1217996110
46
HudsonJ. D.ShoaibiM. A.MaestroR.CarneroA.HannonG. J.BeachD. H. (1999). A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity. J. Exp. Med.190, 1375–1382. 10.1084/jem.190.10.1375
47
JiangT.ZhouC.RenS. (2016). Role of IL-2 in Cancer Immunotherapy. Oncoimmunology5. e116346210.1080/2162402X.2016.1163462
48
JosephP. R. B.MosierP. D.DesaiU. R.RajarathnamK. (2015). Solution NMR Characterization of Chemokine CXCL8/IL-8 Monomer and Dimer Binding to Glycosaminoglycans: Structural Plasticity Mediates Differential Binding Interactions. Biochem. J.472, 121–133. 10.1042/BJ20150059
49
KämpferA. A. M.UrbánP.GioriaS.KanaseN.StoneV.Kinsner-OvaskainenA. (2017). Development of an In Vitro Co-culture Model to Mimic the Human Intestine in Healthy and Diseased State. Toxicol. Vitro45, 31–43. 10.1016/j.tiv.2017.08.011
50
KimH. R. P. M.ParkM. K.ChoM. L.YoonC. H.LeeS. H.ParkS. H.et al (2007). Macrophage Migration Inhibitory Factor Upregulates Angiogenic Factors and Correlates with Clinical Measures in Rheumatoid Arthritis. J. Rheumatol.34, 927–936.
51
KleemannR.KapurniotuA.FrankR. W.GessnerA.MischkeR.FliegerO.et al (1998). Disulfide Analysis Reveals a Role for Macrophage Migration Inhibitory Factor (MIF) as Thiol-Protein Oxidoreductase. J. Mol. Biol.280, 85–102. 10.1006/jmbi.1998.1864
52
KumarA.AbdelmalakB.InoueY.CulverD. A. (2018). Pulmonary Alveolar Proteinosis in Adults: Pathophysiology and Clinical Approach. Lancet Respir. Med.6, 554–565. 10.1016/s2213-2600(18)30043-2
53
KumarS.HanningC. R.Brigham-BurkeM. R.RiemanD. J.LehrR.KhandekarS.et al (2002). Interleukin-1f7b (Il-1h4/Il-1f7) Is Processed By Caspase-1 And Mature Il-1f7b Binds To The Il-18 Receptor But Does Not Induce Ifn-Γ Production. Cytokine18, 61–71. 10.1006/cyto.2002.0873
54
KünzeG.GehrckeJ.-P.PisabarroM. T.HusterD. (2014). NMR Characterization of the Binding Properties and Conformation of Glycosaminoglycans Interacting with Interleukin-10. Glycobiology24, 1036–1049. 10.1093/glycob/cwu069
55
KünzeG.KöhlingS.VogelA.RademannJ.HusterD. (2016). Identification of the Glycosaminoglycan Binding Site of Interleukin-10 by NMR Spectroscopy. J. Biol. Chem.291, 3100–3113. 10.1074/jbc.M115.681759
56
LaiK. N.LeungJ. C.MetzC. N.LaiF. M.BucalaR.LanH. Y. (2003). Role for Macrophage Migration Inhibitory Factor in Acute Respiratory Distress Syndrome. J. Pathol.199, 496–508. 10.1002/path.1291
57
LisiG. P.LoriaJ. P. (2016). Solution NMR Spectroscopy for the Study of Enzyme Allostery. Chem. Rev.116, 6323–6369. 10.1021/acs.chemrev.5b00541
58
Llamas-CovarrubiasM. A.ValleY.Navarro-HernándezR. E.Guzmán-GuzmánI. P.Ramírez-DueñasM. G.Rangel-VillalobosH.et al (2012). Serum Levels of Macrophage Migration Inhibitory Factor Are Associated with Rheumatoid Arthritis Course. Rheumatol. Int.32, 2307–2311. 10.1007/s00296-011-1951-6
59
LotfiN.ThomeR.RezaeiN.ZhangG.-X.RezaeiA.RostamiA.et al (2019). Roles of GM-CSF in the Pathogenesis of Autoimmune Diseases: An Update. Front. Immunol.10, 1265. 10.3389/fimmu.2019.01265
60
LubetskyJ. B.SwopeM.DealwisC.BlakeP.LolisE. (1999). Pro-1 of Macrophage Migration Inhibitory Factor Functions as a Catalytic Base in the Phenylpyruvate Tautomerase Activity,. Biochemistry38, 7346–7354. 10.1021/bi990306m
61
ManiM.ChenC.AmbleeV.LiuH.MathurT.ZwickeG.et al (2015). MoonProt: a Database for Proteins that Are Known to Moonlight. Nucleic Acids Res.43, D277–D282. 10.1093/nar/gku954
62
McGeachyM. J.CuaD. J.GaffenS. L. (2019). The IL-17 Family of Cytokines in Health and Disease. Immunity50, 892–906. 10.1016/j.immuni.2019.03.021
63
MehtaH. M.MalandraM.CoreyS. J. (2015). G-CSF and GM-CSF in Neutropenia. J. Immunol.195, 1341–1349. 10.4049/jimmunol.1500861
64
MilovanovicJ.ArsenijevicA.StojanovicB.KanjevacT.ArsenijevicD.RadosavljevicG.et al (2020). Interleukin-17 in Chronic Inflammatory Neurological Diseases. Front. Immunol.11, 947. 10.3389/fimmu.2020.00947
65
MitchellR. A.LiaoH.ChesneyJ.Fingerle-RowsonG.BaughJ.DavidJ.et al (2002). Macrophage Migration Inhibitory Factor (MIF) Sustains Macrophage Proinflammatory Function by Inhibiting P53: Regulatory Role in the Innate Immune Response. Proc. Natl. Acad. Sci.99, 345–350. 10.1073/pnas.012511599
66
MoyatM.BouzoureneH.OuyangW.IovannaJ.RenauldJ.-C.VelinD. (2017). IL-22-induced Antimicrobial Peptides Are Key Determinants of Mucosal Vaccine-Induced protection against H. pylori in Mice. Mucosal Immunol.10, 271–281. 10.1038/mi.2016.38
67
MühlhahnP.CzischM.GeorgescuJ.RennerC.RossA.HolakT. A.et al (1996). NMR Characterization of Structure, Backbone Dynamics, and Glutathione Binding of the Human Macrophage Migration Inhibitory Factor (MIF). Protein Sci.5, 2095–2103. 10.1002/pro.5560051016
68
MulcahyM. E.LeechJ. M.RenauldJ.-C.MillsK. H.McLoughlinR. M. (2016). Interleukin-22 Regulates Antimicrobial Peptide Expression and Keratinocyte Differentiation to Control Staphylococcus aureus Colonization of the Nasal Mucosa. Mucosal Immunol.9, 1429–1441. 10.1038/mi.2016.24
69
NoeJ. T.MitchellR. A. (2020). MIF-dependent Control of Tumor Immunity. Front. Immunol.11. 60994810.3389/fimmu.2020.609948
70
O'Connor JrW.Jr.KamanakaM.BoothC. J.TownT.NakaeS.IwakuraY.et al (2009). A Protective Function for Interleukin 17A in T Cell-Mediated Intestinal Inflammation. Nat. Immunol.10, 603–609. 10.1038/ni.1736
71
OdaS.OdaT.NishiK.TakabuchiS.WakamatsuT.TanakaT.et al (2008). Macrophage Migration Inhibitory Factor Activates Hypoxia-Inducible Factor in a P53-dependent Manner. PLoS One3, e2215. 10.1371/journal.pone.0002215
72
OnoderaS.TanjiH.SuzukiK.KanedaK.MizueY.SagawaA.et al (1999). High Expression of Macrophage Migration Inhibitory Factor in the Synovial Tissues of Rheumatoid Joints. Cytokine11, 163–167. 10.1006/cyto.1998.0402
73
PantourisG.HoJ.ShahD.SyedM. A.LengL.BhandariV.et al (2018). Nanosecond Dynamics Regulate the MIF‐Induced Activity of CD74. Angew. Chem. Int. Ed.57, 7116–7119. 10.1002/anie.201803191
74
PantourisG.KhuranaL.MaA.SkeensE.ReissK.BatistaV. S.et al (2020). Regulation of MIF Enzymatic Activity by an Allosteric Site at the Central Solvent Channel. Cel Chem. Biol.27, 740–750. e74510.1016/j.chembiol.2020.05.001
75
PantourisG.SyedM. A.FanC.RajasekaranD.ChoT. Y.RosenbergE. M.et al (2015). An Analysis of MIF Structural Features that Control Functional Activation of CD74. Chem. Biol.22, 1197–1205. 10.1016/j.chembiol.2015.08.006
76
ParkS. H.BerkampS.RadoicicJ.De AngelisA. A.OpellaS. J. (2017). Interaction of Monomeric Interleukin-8 with CXCR1 Mapped by Proton-Detected Fast MAS Solid-State NMR. Biophysical J.113, 2695–2705. 10.1016/j.bpj.2017.09.041
77
ParkinsA.SkeensE.McCallumC. M.LisiG. P.PantourisG. (2021). The N-Terminus of MIF Regulates the Dynamic Profile of Residues Involved in CD74 Activation. Biophysical J.120, 3893–3900. 10.1016/j.bpj.2021.08.025
78
PenkA.BaumannL.HusterD.SamsonovS. A. (2019). NMR and Molecular Modeling Reveal Specificity of the Interactions between CXCL14 and Glycosaminoglycans. Glycobiology29, 715–725. 10.1093/glycob/cwz047
79
RighettiR. F.SantosT. M. d.CamargoL. d. N.AristótelesL. R. C. R. B.FukuzakiS.SouzaF. C. R. d.et al (2018). Protective Effects of Anti-IL17 on Acute Lung Injury Induced by LPS in Mice. Front. Pharmacol.9, 1021. 10.3389/fphar.2018.01021
80
RoanF.Obata-NinomiyaK.ZieglerS. F. (2019). Epithelial Cell-Derived Cytokines: More Than Just Signaling the Alarm. J. Clin. Invest.129, 1441–1451. 10.1172/JCI124606
81
RoyU. (2020). Insight into the Structures of Interleukin-18 Systems. Comput. Biol. Chem.88, 107353. 10.1016/j.compbiolchem.2020.107353
82
RozwarskiD. A.DiederichsK.HechtR.BooneT.KarplusP. A. (1996). Refined crystal Structure and Mutagenesis of Human Granulocyte-Macrophage colony-stimulating Factor. Proteins26, 304–313. 10.1002/(sici)1097-0134(199611)26:3<304:Aid-prot6>3.0.Co;2-d
83
SchinaglA.KerschbaumerR. J.SabarthN.DouillardP.ScholzP.VoelkelD.et al (2018). Role of the Cysteine 81 Residue of Macrophage Migration Inhibitory Factor as a Molecular Redox Switch. Biochemistry57, 1523–1532. 10.1021/acs.biochem.7b01156
84
SchlunsK. S.LefrançoisL. (2003). Cytokine Control of Memory T-Cell Development and Survival. Nat. Rev. Immunol.3, 269–279. 10.1038/nri1052
85
ShiomiA.UsuiT.MimoriT. (2016). GM-CSF as a Therapeutic Target in Autoimmune Diseases. Inflamm. Regener36, 8. 10.1186/s41232-016-0014-5
86
SubbannayyaT.VariarP.AdvaniJ.NairB.ShankarS.GowdaH.et al (2016). An Integrated Signal Transduction Network of Macrophage Migration Inhibitory Factor. J. Cel Commun. Signal.10, 165–170. 10.1007/s12079-016-0326-x
87
SunT.HolowkaT.SongY.ZierowS.LengL.ChenY.et al (2012). A Plasmodium-Encoded Cytokine Suppresses T-Cell Immunity during Malaria. Proc. Natl. Acad. Sci.109, E2117–E2126. 10.1073/pnas.1206573109
88
TahvildariM.DanaR. (2019). Low-Dose IL-2 Therapy in Transplantation, Autoimmunity, and Inflammatory Diseases. J.I.203, 2749–2755. 10.4049/jimmunol.1900733
89
TakahashiK.KogaK.LingeH. M.ZhangY.LinX.MetzC. N.et al (2009). Macrophage CD74 Contributes to MIF-Induced Pulmonary Inflammation. Respir. Res.10, 33. 10.1186/1465-9921-10-33
90
ToldiJ.NemethD.HegyiP.MolnarZ.SolymarM.FarkasN.et al (2021). Macrophage Migration Inhibitory Factor as a Diagnostic and Predictive Biomarker in Sepsis: Meta-Analysis of Clinical Trials. Sci. Rep.11, 8051. 10.1038/s41598-021-87613-0
91
Trivedi-ParmarV.JorgensenW. L. (2018). Advances and Insights for Small Molecule Inhibition of Macrophage Migration Inhibitory Factor. J. Med. Chem.61, 8104–8119. 10.1021/acs.jmedchem.8b00589
92
UshachI.ZlotnikA. (2016). Biological Role of Granulocyte Macrophage colony-stimulating Factor (GM-CSF) and Macrophage colony-stimulating Factor (M-CSF) on Cells of the Myeloid Lineage. J. Leukoc. Biol.100, 481–489. 10.1189/jlb.3RU0316-144R
93
ValeriM.RaffatelluM. (2016). Cytokines IL-17 and IL-22 in the Host Response to Infection. Pathog. Dis.74. ftw11110.1093/femspd/ftw111
94
van de VeerdonkF. L.NeteaM. G.DinarelloC. A.JoostenL. A. B. (2011). Inflammasome Activation and IL-1β and IL-18 Processing during Infection. Trends Immunol.32, 110–116. 10.1016/j.it.2011.01.003
95
van NieuwenhuijzeA.KoendersM.RoeleveldD.SleemanM. A.van den BergW.WicksI. P. (2013). GM-CSF as a Therapeutic Target in Inflammatory Diseases. Mol. Immunol.56, 675–682. 10.1016/j.molimm.2013.05.002
96
WangYChenYWangCYangMWangYBaoLWangJEKimBChanKYXuWCapotaEOrtegaJNijhawanDLiGMLuoWWangY (2021). MIF is a 3' flap nuclease that facilitates DNA replication and promotes tumor growth. Nat Commun12, 2954. 10.1038/s41467-021-23264-z
97
WatersL. C.VeverkaV.StrongS. L.MuskettF. W.DediN.LawsonA. D. G.ProsserC. E.TaylorR. J.HenryA. J.CarrM. D. (2021). Conformational dynamics in interleukin 17A and 17F functional complexes is a key determinant of receptor A affinity and specificity. Cytokine142. 15547610.1016/j.cyto.2021.155476
98
WettreichA.SebollelaA.CarvalhoM. A.AzevedoS. P.BorojevicR.FerreiraS. T.Coelho-SampaioT. (1999). Acidic pH modulates the interaction between human granulocyte-macrophage colony-stimulating factor and glycosaminoglycans. Journal of Biological Chemistry274, 31468–31475. 10.1074/jbc.274.44.31468
99
WozniakK. L.HoleC. R.YanoJ.FidelP. L.WormleyF. L. (2014). Characterization of IL-22 and antimicrobial peptide production in mice protected against pulmonary Cryptococcus neoformans infection. Microbiology (Reading)160, 1440–1452. 10.1099/mic.0.073445-0
100
YangC.-Y. (2020). Comparative Analyses of the Conformational Dynamics Between the Soluble and Membrane-Bound Cytokine Receptors. Sci Rep10, 7399. 10.1038/s41598-020-64034-z
101
ZenobiaC.HajishengallisG. (2015). Basic biology and role of interleukin-17 in immunity and inflammation. Periodontol 200069, 142–159. 10.1111/prd.12083
Summary
Keywords
cytokine, protein dynamics, immunology, spectroscopy, allostery
Citation
Cui JY and Lisi GP (2021) Molecular Level Insights Into the Structural and Dynamic Factors Driving Cytokine Function. Front. Mol. Biosci. 8:773252. doi: 10.3389/fmolb.2021.773252
Received
09 September 2021
Accepted
06 October 2021
Published
25 October 2021
Volume
8 - 2021
Edited by
Yong Wang, Zhejiang University, China
Reviewed by
Hongbin Wan, Novartis Institutes for BioMedical Research, United States
Chao-Yie Yang, University of Tennessee Health Science Center (UTHSC), United States
Hao-Jen Hsu, Tzu Chi University, Taiwan
Updates
Copyright
© 2021 Cui and Lisi.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: George P. Lisi, george_lisi@brown.edu
This article was submitted to Biophysics, a section of the journal Frontiers in Molecular Biosciences
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.